Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor

Journal of Internal Medicine

Volumn 254, Issue 4, 2003, Pages 313-321

  Lee, Agnes Y Y ^a,c   Vlasuk, G P ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b Dendreon   (United States)

^c HENDERSON GENERAL HOSPITAL   (Canada)

Author keywords

Anticoagulant; Factor VIIa; Recombinant nematode anticoagulant protein c2; Thrombosis; Tissue factor

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; AMINO ACID; ANTICOAGULANT PROTEIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; CLOPIDOGREL; COUMARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ATTENUATION; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TOLERANCE; ENZYME INHIBITION; HUMAN; NONHUMAN; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOSIS; TOTAL KNEE REPLACEMENT; VENOUS STASIS;

ANTICOAGULANTS; BLOOD COAGULATION; FACTOR VIIA; FACTOR X; FACTOR XA; HELMINTH PROTEINS; HUMANS; RECOMBINANT PROTEINS; THROMBOPLASTIN; THROMBOSIS; VENOUS THROMBOSIS;

EID: 0141862287     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01224.x     Document Type: Conference Paper

References (49)

1. Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
2. Hirsh J, Dalen J, Anderson DR et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
3. Weitz JI, Hirsh J. New anticoagulant drugs. Chest 2001; 119: 95S-107S.
4. Rao LVM, Ezban M. Acitve site-blocked activated factor VII as an effective antithrombotic agent: mechanism of action. Blood Coagul Fibrinolysis 2000; 11: S135-43.
5. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-72.
6. Presta L, Sims P, Meng YG et al. Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost 2001; 85: 379-89.
7. Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001; 86: 66-74.
8. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165-74.
9. Loeb L, Smith AJ. The presence of a substance inhibiting the coagulation of blood in Ancylostoma. Proc Pathol Soc Philadelphia 1904; 7: 173-8.
10. Stanssens P, Bergum PW, Gansemans Y et al. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci USA 1996; 93: 2149-54.
11. Bergum PW, Cruikshank A, Maki SL, Kelly CR, Ruf W, Vlasuk GP. Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2. J Biol Chem 2001; 276: 10 063-71.
12. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-3.
13. Buddai SK, Toulokhonova L, Bergum PW, Vlasuk GP, Krishnaswamy S. Nematode anticoagulant protein c2 reveals a site on factor Xa that is important for macromolecular substrate binding to human prothrombinase. J Biol Chem 2002; 277: 26 689-98.
14. Coughlin SR, Camerer E. Participation in inflammation. J Clin Invest 2003; 111: 25-7.
15. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 2001; 98: 7742-7.
16. Baugh RJ, Broze GJ Jr, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem 1998; 273: 4378-86.
17. Vlasuk GP, Bradbury AE, Bergum PW, Rote WE. Early clinical evaluation of rNAPc2, a novel inhibitor of blood coagulation factor VIIa/tissue factor (fVIIa/TF). J Am Coll Cardiol 1999; 33: 255a-6a.
18. Vlasuk GP, Bradbury A, Lopez-Kinniger L et al. Pharmokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant rematode anticoagulant protein c2 following subcutaneous administration in man. Thromb Haemost 2003: in press.
19. Harker LA, Hanson SR, Kelly AB. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb Haemost 1995; 74: 464-72.
20. Lee A, Agnelli G, Büller H et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104: 74-8.
21. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest 2001; 119: 132S-75S.
22. Brookenthal KR, Freedman KB, Lotke PA, Fitzgerald RH, Lonner JH. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty 2001; 16: 293-300.
23. Moons A, Peter RJG, Bijsterveld NR et al. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronoary angioplasty. J Am Coll Cardiol 2003; 41: 2147-53.
24. Hedner U, Erhardtsen E. Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI. Ann Med 2000; 32 (Suppl 1): 68-72.
25. Kottke-Marchant K, Munzel T, Brooks L, Borzi L, Sapp SK, Ribel M. The effect of active site-inhibited factor seven (ASIS) on hemostatic activation in percutaneoul coronary intervention. Circulation 2000; 102: ii300.
26. Lincoff AM. First clinical investigation of a tissue factor inhibitor administered during percutaneous coronary revascularization: a randomized, double-blind, dose-escalation trial-assessing safety and efficacy of FFR-FVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial. J Am Coll Cardiol 2000; 36: 312-3.
27. Lev EI, Marmur JD, Zdravkovic M et al. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study. Arterioscler Thromb Vasc Biol 2002; 22: 1036-41.
28. Friederich PW, Levi M, Bauer KA et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 2001; 103: 2555-9.
29. Øterud B, Björklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 605-17.
30. Versteeg HH, Peppelenbosch MP, Spek CA. The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling? Thromb Haemost 2001; 86: 1353-9.
31. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001; 86: 51-6.
32. van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 639-51.
33. Levi M. Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. J Crit Care 2001; 16: 167-77.
34. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-25.
35. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
36. Taylor FB, Chang AC, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood 1998; 91: 1609-15.
37. Taylor FB Jr, Chang A, Ruf W et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-34.
38. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-6.
39. Doshi SN, Marmur JD. Evolving role of tissue factor and its pathway inhibitor. Crit Care Med 2002; 30: S241-50.
40. Abraham E, Reinhart K, Svoboda P et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29: 2081-9.
41. de Pont A-C, Moons HM, de Jonge E et al. Recombinant nematode anticoagulant protein c2 (rNAPc2), an inhibitor of tissue factor/factor VIIa, attenuates coagulation and IL-10 response in human endotoxemia. Blood 2002; 100: 487a.
42. de Jonge E, Dekkers PE, Creasey AA et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-9.
43. Jilma B, Marsik C, Mayr F et al. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans, Clin Pharmacol Ther 2002; 72: 403-10.
44. Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia 2001; 3: 371-84.
45. Rickles FR. Relationship of blood clotting and tumor angiogenesis. Haemostasis 2001; 31 (Suppl 1): 16-20.
46. Konigsberg W, Kirchhofer D, Riederer MA, Nemerson Y. The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis. Thromb Haemost 2001; 86: 757-71.
47. Ruf W. Molecular regulation of blood clotting in tumor biology. Haemostasis 2001; 31 (Suppl 1): 5-7.
48. Hembrough TA, Swartz GM, Papathanassiu A et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003; 63: 2997-3000.
49. Amirkhosravi A, Meyer T, Chang JY et al. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002; 87: 930-6.